Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
biotech
5
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
5
×
detroit blog main
detroit top stories
immunotherapy
5
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
cancer
cancer immunotherapy
cell therapy
gene therapy
gilead sciences
glaxosmithkline
nonalcoholic steatohepatitis
abeona therapeutics
What
roundup
bio
drug
nash
new
news
abbvie’s
according
advantages
ahead
akcea
american
annual
approval
ash
bar
biofourmis
biogen’s
biopharmaceutical
biotech
blood
borne
brings
bucks
cancer
cancers
cases
celebrate
centers
chance
cigarettes
companies
conference
control
convo
corner
day
days
deaths
diego
Language
unset
Current search:
biotech
×
novartis
×
photo
×
" clinical trials "
×
immunotherapy
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More